Beta Bionics Faces Securities Fraud Suit Over iLet Pump Disclosures
Los Angeles – September 11, 2026 -- DJS Law Group has reminded shareholders of a class action lawsuit filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The suit covers investors who purchased BBNX shares between September 11, 2026 and September 11, 2026, with a lead plaintiff filing deadline set for September 11, 2026.
Complaint alleges Beta Bionics downplayed FDA findings on its iLet insulin pump
The complaint centers on the iLet Bionic Pancreas insulin pump, Beta Bionics' sole commercialized product. After the company disclosed that the FDA had issued a Form 483 following a manufacturing facility inspection, defendants allegedly told investors the agency's observations were limited to complaint-reporting criteria and did not reflect underlying device problems.